Opinion/decision on a Paediatric investigation plan (PIP): Tavlesse, Fostamatinib, decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Haematology-Hemostaseology;Immunology-Rheumatology-Trans

Opinion/decision on a Paediatric investigation plan (PIP): Tavlesse, Fostamatinib, decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Haematology-Hemostaseology;Immunology-Rheumatology-Transplantation, PIP number: P/0027/2022

Opinion/decision on a Paediatric investigation plan (PIP): Alecensa, Alectinib, decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), therapeutic area: Oncology, PIP number: P/0006/2022

Opinion/decision on a Paediatric investigation plan (PIP): Alecensa, Alectinib, decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s), therapeutic area: Oncology, PIP number: P/0006/2022

Meeting of the Medicine Shortages Single Point of Contact (SPOC) Working Party, Online, from 22 January 2024, 10:00 (CET) to 22 January 2024, 13:30 (CET)

Meeting of the Medicine Shortages Single Point of Contact (SPOC) Working Party, Online, from 22 January 2024, 10:00 (CET) to 22 January 2024, 13:30 (CET)

Paediatric Committee (PDCO): 16-19 January 2024, European Medicines Agency, Amsterdam, the Netherlands, from 16 January 2024 to 19 January 2024

Paediatric Committee (PDCO): 16-19 January 2024, European Medicines Agency, Amsterdam, the Netherlands, from 16 January 2024 to 19 January 2024

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.